Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...
Breast cancer was never on my radar. After all, I learned long ago that I don't have the BRCA1 or 2 gene mutations, and I have no family history of the disease. So, for most of my adult life I took ...
The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.